Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
28
RKV.V Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
-12.83%
Day range:
$0.10 - $0.11
52-week range:
$0.09 - $2.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.08x
Volume:
190.7K
Avg. volume:
41K
1-year change:
-93.75%
Market cap:
$2.1M
Revenue:
--
EPS (TTM):
-$0.57
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RKV.V
Rakovina Therapeutics, Inc.
|
-- | -- | -- | -- | $0.40 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RKV.V
Rakovina Therapeutics, Inc.
|
$0.10 | $0.40 | $2.1M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $9.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RKV.V
Rakovina Therapeutics, Inc.
|
56.95% | -4.118 | 33.64% | 0.38x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RKV.V
Rakovina Therapeutics, Inc.
|
-$135.1K | -$1.6M | -170.68% | -275.65% | -- | -$1.2M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Rakovina Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RKV.V or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Rakovina Therapeutics, Inc.'s net margin of --. Rakovina Therapeutics, Inc.'s return on equity of -275.65% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RKV.VRakovina Therapeutics, Inc.-- -$0.08 $4.6M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About RKV.V or COOL.CX?
Rakovina Therapeutics, Inc. has a consensus price target of $0.40, signalling upside risk potential of 3900%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Rakovina Therapeutics, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Rakovina Therapeutics, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RKV.VRakovina Therapeutics, Inc.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is RKV.V or COOL.CX More Risky?
Rakovina Therapeutics, Inc. has a beta of -0.385, which suggesting that the stock is 138.48% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock RKV.V or COOL.CX?
Rakovina Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rakovina Therapeutics, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RKV.V or COOL.CX?
Rakovina Therapeutics, Inc. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Rakovina Therapeutics, Inc.'s net income of -$1.8M is higher than Core One Labs, Inc.'s net income of --. Notably, Rakovina Therapeutics, Inc.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rakovina Therapeutics, Inc. is -- versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RKV.VRakovina Therapeutics, Inc.-- -- -- -$1.8M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns RKV.V or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Rakovina Therapeutics, Inc.'s net margin of --. Rakovina Therapeutics, Inc.'s return on equity of -275.65% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RKV.VRakovina Therapeutics, Inc.-- -$0.08 $4.6M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About RKV.V or CURE.X.CX?
Rakovina Therapeutics, Inc. has a consensus price target of $0.40, signalling upside risk potential of 3900%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Rakovina Therapeutics, Inc. has higher upside potential than Biocure Technology, analysts believe Rakovina Therapeutics, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings RKV.VRakovina Therapeutics, Inc.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is RKV.V or CURE.X.CX More Risky?
Rakovina Therapeutics, Inc. has a beta of -0.385, which suggesting that the stock is 138.48% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RKV.V or CURE.X.CX?
Rakovina Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rakovina Therapeutics, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RKV.V or CURE.X.CX?
Rakovina Therapeutics, Inc. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Rakovina Therapeutics, Inc.'s net income of -$1.8M is higher than Biocure Technology's net income of --. Notably, Rakovina Therapeutics, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rakovina Therapeutics, Inc. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RKV.VRakovina Therapeutics, Inc.-- -- -- -$1.8M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns RKV.V or HEAL.CX?
has a net margin of -- compared to Rakovina Therapeutics, Inc.'s net margin of --. Rakovina Therapeutics, Inc.'s return on equity of -275.65% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RKV.VRakovina Therapeutics, Inc.-- -$0.08 $4.6M HEAL.CX-- -- -- -
What do Analysts Say About RKV.V or HEAL.CX?
Rakovina Therapeutics, Inc. has a consensus price target of $0.40, signalling upside risk potential of 3900%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Rakovina Therapeutics, Inc. has higher upside potential than , analysts believe Rakovina Therapeutics, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings RKV.VRakovina Therapeutics, Inc.0 0 0 HEAL.CX0 0 0 -
Is RKV.V or HEAL.CX More Risky?
Rakovina Therapeutics, Inc. has a beta of -0.385, which suggesting that the stock is 138.48% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RKV.V or HEAL.CX?
Rakovina Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rakovina Therapeutics, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RKV.V or HEAL.CX?
Rakovina Therapeutics, Inc. quarterly revenues are --, which are larger than quarterly revenues of --. Rakovina Therapeutics, Inc.'s net income of -$1.8M is higher than 's net income of --. Notably, Rakovina Therapeutics, Inc.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rakovina Therapeutics, Inc. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RKV.VRakovina Therapeutics, Inc.-- -- -- -$1.8M HEAL.CX-- -- -- --
-
Which has Higher Returns RKV.V or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -- compared to Rakovina Therapeutics, Inc.'s net margin of --. Rakovina Therapeutics, Inc.'s return on equity of -275.65% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RKV.VRakovina Therapeutics, Inc.-- -$0.08 $4.6M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About RKV.V or LOBE.CX?
Rakovina Therapeutics, Inc. has a consensus price target of $0.40, signalling upside risk potential of 3900%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 14192.33%. Given that Lobe Sciences Ltd. has higher upside potential than Rakovina Therapeutics, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Rakovina Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RKV.VRakovina Therapeutics, Inc.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is RKV.V or LOBE.CX More Risky?
Rakovina Therapeutics, Inc. has a beta of -0.385, which suggesting that the stock is 138.48% less volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock RKV.V or LOBE.CX?
Rakovina Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rakovina Therapeutics, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RKV.V or LOBE.CX?
Rakovina Therapeutics, Inc. quarterly revenues are --, which are smaller than Lobe Sciences Ltd. quarterly revenues of --. Rakovina Therapeutics, Inc.'s net income of -$1.8M is lower than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Rakovina Therapeutics, Inc.'s price-to-earnings ratio is -- while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rakovina Therapeutics, Inc. is -- versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RKV.VRakovina Therapeutics, Inc.-- -- -- -$1.8M LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns RKV.V or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Rakovina Therapeutics, Inc.'s net margin of --. Rakovina Therapeutics, Inc.'s return on equity of -275.65% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RKV.VRakovina Therapeutics, Inc.-- -$0.08 $4.6M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About RKV.V or NSHS.CX?
Rakovina Therapeutics, Inc. has a consensus price target of $0.40, signalling upside risk potential of 3900%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Rakovina Therapeutics, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Rakovina Therapeutics, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RKV.VRakovina Therapeutics, Inc.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is RKV.V or NSHS.CX More Risky?
Rakovina Therapeutics, Inc. has a beta of -0.385, which suggesting that the stock is 138.48% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock RKV.V or NSHS.CX?
Rakovina Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rakovina Therapeutics, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RKV.V or NSHS.CX?
Rakovina Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Rakovina Therapeutics, Inc.'s net income of -$1.8M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Rakovina Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rakovina Therapeutics, Inc. is -- versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RKV.VRakovina Therapeutics, Inc.-- -- -- -$1.8M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
